Extremely Prolonged INR Associated with Warfarin in Combination with Both Trazodone and Omega-3 Fatty Acids

Archives of Medical Research

Volumn 38, Issue 8, 2007, Pages 901-904

  Jalili, Mohammad ^a   Dehpour, Ahmad Reza ^b  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Drug interaction; Fish oil; Omega 3 polyunsaturated fatty acid; Trazodone; Warfarin

Indexed keywords

FISH OIL; OMEGA 3 FATTY ACID; TRAZODONE; VITAMIN K GROUP; WARFARIN;

AGED; ANAMNESIS; ANTICOAGULATION; ARTICLE; BLOOD CLOTTING; CASE REPORT; CLINICAL FEATURE; EMERGENCY WARD; HOSPITAL ADMISSION; HUMAN; INTERNATIONAL NORMALIZED RATIO; MALE; THROMBOCYTE AGGLUTINATION;

AGED; ANTICOAGULANTS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; DRUG INTERACTIONS; FATTY ACIDS, OMEGA-3; FOLLOW-UP STUDIES; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; PROTHROMBIN TIME; TIME FACTORS; TRAZODONE; WARFARIN;

EID: 34848831836     PISSN: 01884409     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.arcmed.2007.05.004     Document Type: Article

References (15)

1. Majerus P.W., and Tollefsen D.M. Anticoagulant, thrombolytic, and antiplatelet drugs. In: Hardman J.G., and Limbird L.E. (Eds). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 10th ed. (2001), McGraw-Hill, New York 1519-1538
2. Erdman S.M., Rodvold K.A., and Friedenburg W.R. Thromboembolic disorders. In: DiPiro J.T., Talbert R.L., Yee G.C., Matzke G.R., Wells B.G., and Posey L.M. (Eds). Pharmacotherapy: A Pathophysiologic Approach. 3rd ed. (1996), Appleton & Lange, Stamford, CT 399-433
3. Hirsh J., Dalen J.E., Anderson D.R., Poller L., Buseey H., Ansell J., et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 114 Suppl 5 (1998) 445s-469s
4. Murphy D.L. Neuropsychiatric disorders and the multiple human brain serotonin receptor subtypes and subsystems. Neuropsychopharmacology 3 (1990) 457-471
5. Ellis A.M., and Coker S.J. Contribution of antiplatelet activity to the effects of 5-HT2 receptor antagonist on reperfusion-induced arrhythmia in anesthetized rats. Eur J Pharmacol 219 (1992) 97-104
6. Hardy J.L., and Sirois A. Reduction of prothrombin and partial thromboplastin times with trazodone. CMAJ 135 (1986) 1372
7. Small N.L., and Giamonna K.A. Interaction between warfarin and trazodone. Ann Pharmacother 34 (2000) 734-736
8. Fish and Omega-3 fatty acids. AHA Recommendation; www.americanheart.org/presenter.jhtml?identifier=4632 (accessed 2005 May 25).
9. FDA press release: FDA announces qualified health claims for omega-3 fatty acids www.fda.gov/bbs/topics/news/2004/NEW01115.html (accessed 2005 May 22).
10. Holub B.J. Clinical nutrition: 4. Omega-3 fatty acids in cardiovascular care. CMAJ 166 (2002) 608-615
11. Nieuwenhuys C.M.A., Beguin S., Offermans R.F.G., Emeis J.J., Hornstra G., and Heemskerk J.W.M. Hypocoagulant and lipid-lowering effects of dietary N-3 polyunsaturated fatty acids with unchanged platelet activation in rats. Arterioscler Thromb Vasc Biol 18 (1998) 1480-1489
12. Archer S.L., Green D., Chamberlain M., Dyer A.R., and Liu K. Association of dietary fish and n-3 fatty acid intake with hemostatic factors in the coronary artery risk development in young adults (CARDIA) study. Arterioscler Thromb Vasc Biol 18 (1998) 1119-11123
13. Nieuwenhuys C.M.A., Feijge M.A.H., Vermeer C., Hennissen A.H.H.M., Beguin S., and Heemskerk J.W.M. Vitamin K-dependent and vitamin K-independent hypocoagulant effects of dietary fish oil in rats. Thromb Res 104 (2001) 137-147
14. Buckley M.S., Goff A.D., and Knapp W.E. Fish oil interaction with warfarin. Ann Pharmacother 38 (2004) 50-53
15. Naranjo C.A., Busto U., Sellers E.M., Sandor P., Ruiz I., Roberts E.A., et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 30 (1981) 239-245